The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ACR Publishes New Guide for RA Care

ACR Publishes New Guide for RA Care

July 1, 2008 • By Terry Hartnett

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On June 15, the ACR published formal recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). “The ACR is moving toward a formal process for evidence-based [clinical practice] recommendations that is based on the current state of the art of [rheumatology] practice,” says Kenneth G. Saag, MD, MSc, professor of medicine in the division of clinical immunology and rheumatology at the University of Alabama at Birmingham. He co-authored the guidelines, which were published in Arthritis Care & Research, with Daniel Furst, MD, professor of medicine/rheumatology at the University of California, Los Angeles Medical Center.1

You Might Also Like
  • 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts
Explore This Issue
July 2008
Also By This Author
  • Pediatric BOOST

“These are reference standards for the rheumatologist in daily practice; they are not meant to be proscriptive,” Dr. Saag emphasizes. He likewise stresses that the new guidelines are not comprehensive. “There are a large and extensive number of recommendations, but they are not exhaustive,” says Dr. Saag. “There were areas of practice for which the expert panel thought that there was an absence of evidence and consensus,” he says. “Applying these recommendations to clinical practice requires individualized patient assessment and clinical decision making,” write Drs. Saag, Furst, and colleagues in the published article on the guidelines.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For the average rheumatologist who treats patients in his or her practice every day—and for those “steeped in current practice”—there are no surprises in the guidelines, Daniel Hal Solomon, MD, MPH, head of the ACR committee that reviewed the guidelines, tells The Rheumatologist. “The last guidelines were issued in 2002, and did not include recommendations for the use of biologic agents, so they needed to be updated. But these recommendations should not be new for doctors in practice who are current,” he says. “Typically, most rheumatologists are likely to find that these recommendations are in keeping with what they are already doing in practice.” says Dr. Solomon, who is associate professor of medicine and associate chief of Harvard Medical School’s division of pharmacoepidemiology and pharmacoeconomics in Boston, and a member of The Rheumatologist’s editorial board.

The value of the guidelines, say Drs. Solomon and Saag, is that all of the information is synthesized into one document. They are also important for nonspecialists who may not have as much experience in managing patients with RA. “The recommendations are meant to be a document that suggests ways to approach the patient in certain stages of the disease and to outline the safe and effective use of DMARDs,” says Dr. Saag.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A Formal Process

The DMARD guidelines are the first published by ACR that follow from a formal group process. Previous ACR guidelines were developed by an informal consensus approach. Dr. Saag explains the first step in development of these formal guidelines was the review of up-to-date scientific evidence to serve as evidence of current established practice. The DMARD guidelines include a review of literature that was available through February 2007. “We reviewed evidence based on the five treatment domains established by ACR for rheumatoid arthritis,” says Dr. Saag. These are: indications for use, screening for tuberculosis (TB) (biologic DMARDs only), monitoring for side effects, assessing clinical response, and roles of cost and patient preferences in decision making (biologic DMARDs only).

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: Clinical Guidelines, Diagnostic Criteria, Rheumatoid arthritis, TreatmentIssue: July 2008

You Might Also Like:
  • 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis
  • 2014 ACR/ARHP Annual Meeting: Rheumatoid Arthritis Management Treatment Recommendations
  • ACR Urges CMMI to Test Transparently: Coalition offers principles to guide CMS’s care innovation efforts
  • ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.